ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned

Viviani, Simonetta; Zinzani, Pier Luigi; Rambaldi, Alessandro; Brusamolino, Ercole; Levis, Alessandro; Bonfante, V.; Vitolo, Umberto; Pulsoni, Alessandro; Liberati, Anna Marina; Specchia, Giorgina; Valagussa, Pinuccia; Rossi, Andrea; Zaja, Francesco; Pogliani, Enrico Maria; Pregno, Patrizia; Gotti, Manuel; Gallamini, Andrea; Scalabrini, Delia Rota; Bonadonna, Gianni; Gianni, Alessandro M.

doi:10.1056/nejmoa1100340

Cited by 368 publications

(248 citation statements)

References 23 publications

Supporting

Mentioning

225

Contrasting

Unclassified

Order By: Relevance

“…Approximately 30%-40% of patients with advanced Hodgkin lymphoma (HL) disease are refractory to frontline therapy or will relapse after first-line treatment [1,2]. The standard treatment for patients with HL who are unresponsive to frontline therapy or relapse after primary treatment consists of salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients

et al. 2015

Self Cite

View full text Add to dashboard Cite

Background. Hodgkin lymphoma (HL) is characterized by the presence of CD30-positive Hodgkin Reed-Sternberg cells. Approximately 30%-40% of patients with advanced disease are refractory to frontline therapy or will relapse after first-line treatment. The standard management of these patients is salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (ASCT).Thebestprognostic factoristhestatus ofdisease before ASCT; in particular, the normalization of positron emission tomography (PET) scan. Brentuximab vedotin (BV) has shown a high overall response rate in refractory/relapsed HL after ASCT, whereas few data are available regarding its role before ASCT. Patients and Methods. A multicenter, retrospective, observational study was conducted.The primary endpoint of the study was the effectiveness of BV as single agent in patients with

show abstract

Section: Introductionmentioning

confidence: 99%

Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…This approach has been tested in a randomized trial comparing ABVD chemotherapy versus escalated BEACOPP chemotherapy but with an analysis after all treatment has been completed, meaning that initial chemotherapy and subsequent salvage approaches were included in the analysis [12]. In this study, the freedom from first progression was superior to patients receiving escalated BEACOPP with a 7-year freedom from first progression of 85% in the escalated BEACOPP group compared to 73% in the ABVD chemotherapy group.…”

Section: Initial Chemotherapy Approachesmentioning

confidence: 99%

“…The escalated BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) was developed by the German Hodgkin Lymphoma Study Group and has been compared to ABVD chemotherapy in randomized control trials [10][11][12]. These studies have shown a higher complete response rate and improved progression free survival with the use of escalated BEACOPP.…”

Section: Initial Chemotherapy Approachesmentioning

confidence: 99%

Hodgkin lymphoma: MOPP chemotherapy to PD‐1 blockade and beyond

Ansell

2015

American J Hematol

View full text Add to dashboard Cite

Hodgkin lymphoma is a rare lymphoid malignancy affecting~9,200 new patients in the United States annually. Progress in the management of this disease over the past 50 years has been remarkable and the prognosis of this malignancy has changed from a uniformly fatal process to one in which the vast majority of patients are expected to be cured. This remarkable progress has been due to the use of combination approaches incorporating chemotherapy and radiation therapy, and now more recently antibody-drug conjugates and immune checkpoint inhibitors. The goal for the future is to develop treatment combinations that successfully treat all patients and markedly decrease the long-term side effects.

show abstract

“…[72][73][74][75] However, some of these studies were not sufficiently powered to determine differences in OS due to small patient numbers. The EORTC 20012 trial evaluated BEACOPP (4 cycles of escalated-dose and 4 cycles of standard-dose) and ABVD (8 cycles) in high-risk patients with stage III-IV disease and IPS ≥3 (274 patients in the BEACOPP arm and 275 patients in the ABVD arm).…”

Section: Stage Iii-ivmentioning

confidence: 99%

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Hoppe¹,

Advani²,

Ai³

et al. 2017

J Natl Compr Canc Netw

View full text Add to dashboard Cite

OverviewHodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Most patients are diagnosed between 15 and 30 years of age, followed by another peak in adults aged ≥55 years. In 2017, an estimated 8,260 people will be diagnosed with HL in the United States and 1,070 will die of the disease. AbstractThis portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects. Please NoteThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

show abstract

ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned

Abstract: Treatment with BEACOPP, as compared with ABVD, resulted in better initial tumor control, but the long-term clinical outcome did not differ significantly between the two regimens. (Funded by Fondazione Michelangelo; ClinicalTrials.gov number, NCT01251107.).

Cited by 368 publications

References 23 publications

Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients

Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients

Hodgkin lymphoma: MOPP chemotherapy to PD‐1 blockade and beyond

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Contact Info

Product

Resources

About